13th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices

13th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices is organized by Complete Conference Management (CCM) and would be held on Apr 07, 2017 at Estancia La Jolla Hotel & Spa, La Jolla, California, United States of America.

Course Description
• The most recent ACC/AHA guidelines and the integration of new biomarkers plus new application of existing biomarkers
• Examination of the evolving utility of cardiac necrosis biomarkers in Acute Coronary Syndromes, Heart Failure, and other cardiac injuries
• Review of the latest clinical data associated with biomarkers in cardiovascular disease risk prediction and clinical management of disease
• Integration of biomarker data in comorbid conditions including renal disease, diabetes and pulmonary disease
• The application of biomarkers in therapeutic and device trials as qualification criteria, surrogate endpoints, etc.

Objectives
At the conclusion of this activity, participants should be able to:
• Describe the current standards of care associated with the application of biomarkers in cardiac clinical care.
• Cite recent literature that provides an evidence-basis for the diagnostic, prognostic and management applications of cardiac biomarkers.
• Discuss the future biomarker applications in cardiac disease based on recent-breaking clinical studies and clinical trials.
• Assess the effects of PCSK9 inhibition on various lipid biomarkers, and discuss their role in the management of dyslipidemia in various patient populations.
• Identify how the novel ARNI heart failure medication class impacts the interpretation of various cardiovascular biomarkers.
• Apply non-traditional biomarkers including heart rate, serum sodium concentration, the apnea-hypopnia index and pulmonary artery pressure to guide and improve the treatment of patients with cardiovascular disease.
• Apply biomarkers to help optimize selection of patients for cardiac devices, assess for response to device therapy, and improve prognostication of patients with devices.
• Identify novel mobile technologies, applications, and devices that are impacting patient care and personalized medicine, and describe various ways they are being used.